Denali Therapeutics Inc. (DNLI) Free cash flow 2016–2025
Denali Therapeutics Inc. (DNLI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$422.1MFY2025 · since FY2016: -$78.0M → -$422.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$422.1M | -16.1% |
| FY2024 | -$363.6M | +2.0% |
| FY2023 | -$370.9M | -41.3% |
| FY2022 | -$262.5M | -19.4% |
| FY2021 | -$219.9M | -153.2% |
| FY2020 | $413.1M | +343.7% |
| FY2019 | -$169.5M | -462.8% |
| FY2018 | $46.7M | +158.8% |
| FY2017 | -$79.5M | -1.9% |
| FY2016 | -$78.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net incomeDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Operating cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →